CH BIOTECH SER Finalizes $35 Million Convertible Bond Offering

Stock News

Feb 23

CH BIOTECH SER (08037) has announced that all conditions precedent under the subscription agreement have been satisfied. The issuance of convertible bonds with a total principal amount of $35 million to the subscriber was completed on February 20, 2026, in accordance with the terms and conditions of the subscription agreement.

Prior to this issuance, there remained outstanding 2024 convertible bonds with a principal amount of $6 million. These bonds were convertible into a total of 39.25 million shares at a conversion price of HK$1.20 per share.

Following the completion of the new convertible bond issuance on February 20, 2026, as stipulated by the terms of the 2024 convertible bonds, the conversion price for the 2024 bonds has been adjusted from HK$1.20 per share to HK$1.11 per share. Consequently, the maximum number of shares to be issued by the company upon the full conversion of the 2024 convertible bonds is now 42.4324 million shares. This adjustment is effective from February 20, 2026, the completion date of the new bond issuance.

All other terms of the 2024 convertible bonds remain unchanged aside from the aforementioned adjustment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1196102555"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196102555\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196102555?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-23 08:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196102555","market":"sg","top_or_hot":-1,"title":"CH BIOTECH SER Finalizes $35 Million Convertible Bond Offering","media":"Stock News","content":"<p>CH BIOTECH SER (08037) has announced that all conditions precedent under the subscription agreement have been satisfied. The issuance of convertible bonds with a total principal amount of $35 million to the subscriber was completed on February 20, 2026, in accordance with the terms and conditions of the subscription agreement.</p>\n<p>Prior to this issuance, there remained outstanding 2024 convertible bonds with a principal amount of $6 million. These bonds were convertible into a total of 39.25 million shares at a conversion price of HK$1.20 per share.</p>\n<p>Following the completion of the new convertible bond issuance on February 20, 2026, as stipulated by the terms of the 2024 convertible bonds, the conversion price for the 2024 bonds has been adjusted from HK$1.20 per share to HK$1.11 per share. Consequently, the maximum number of shares to be issued by the company upon the full conversion of the 2024 convertible bonds is now 42.4324 million shares. This adjustment is effective from February 20, 2026, the completion date of the new bond issuance.</p>\n<p>All other terms of the 2024 convertible bonds remain unchanged aside from the aforementioned adjustment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CH BIOTECH SER Finalizes $35 Million Convertible Bond Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCH BIOTECH SER Finalizes $35 Million Convertible Bond Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-23 08:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CH BIOTECH SER (08037) has announced that all conditions precedent under the subscription agreement have been satisfied. The issuance of convertible bonds with a total principal amount of $35 million to the subscriber was completed on February 20, 2026, in accordance with the terms and conditions of the subscription agreement.</p>\n<p>Prior to this issuance, there remained outstanding 2024 convertible bonds with a principal amount of $6 million. These bonds were convertible into a total of 39.25 million shares at a conversion price of HK$1.20 per share.</p>\n<p>Following the completion of the new convertible bond issuance on February 20, 2026, as stipulated by the terms of the 2024 convertible bonds, the conversion price for the 2024 bonds has been adjusted from HK$1.20 per share to HK$1.11 per share. Consequently, the maximum number of shares to be issued by the company upon the full conversion of the 2024 convertible bonds is now 42.4324 million shares. This adjustment is effective from February 20, 2026, the completion date of the new bond issuance.</p>\n<p>All other terms of the 2024 convertible bonds remain unchanged aside from the aforementioned adjustment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1219","symbol_name":"保健护理服务","start_time":0,"source_url":"","article_id":"1196102555","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196102555","pubTimestamp":1771806619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CH BIOTECH SER (08037) has announced that all conditions precedent under the subscription agreement have been satisfied. The issuance of convertible bonds with a total principal amount of $35 million...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1219":"保健护理服务","08037":"中国生物科技服务","BK1511":"疑似财技股"},"translate_title":"CH BIOTECH SER完成3500万美元可转换债券发行","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08037":1},"content_text":"CH BIOTECH SER (08037) has announced that all conditions precedent under the subscription agreement have been satisfied. The issuance of convertible bonds with a total principal amount of $35 million to the subscriber was completed on February 20, 2026, in accordance with the terms and conditions of the subscription agreement.\nPrior to this issuance, there remained outstanding 2024 convertible bonds with a principal amount of $6 million. These bonds were convertible into a total of 39.25 million shares at a conversion price of HK$1.20 per share.\nFollowing the completion of the new convertible bond issuance on February 20, 2026, as stipulated by the terms of the 2024 convertible bonds, the conversion price for the 2024 bonds has been adjusted from HK$1.20 per share to HK$1.11 per share. Consequently, the maximum number of shares to be issued by the company upon the full conversion of the 2024 convertible bonds is now 42.4324 million shares. This adjustment is effective from February 20, 2026, the completion date of the new bond issuance.\nAll other terms of the 2024 convertible bonds remain unchanged aside from the aforementioned adjustment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}